Fenoldopam: Prevention of Contrast Media Nephrotoxicity

Abstract

Off-Label Drug Uses — This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Facts and Comparisons. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses. This new guide to the literature will enable the health care professional/clinician to quickly identify published studies on off-label uses and to determine if a specific use is rational in a patient care scenario. The most relevant data are provided in tabular form so that the reader can easily identify the scope of information available. A summary of the data—including, background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations—precedes each table of published studies. References direct the reader to the full literature for more comprehensive information prior to patient care decisions. Direct questions or comments on “Off-Label Drug Uses” to hospitalpharmacy@drugfacts.com.

Get full access to this article

View all access options for this article.

References

Kini

, Sharma

S.K.

Managing the high-risk patient: Experience with fenoldopam, a selective dopamine receptor agonist, in prevention of radiocontrast nephropathy during a percutaneous coronary intervention. Rev Cardiovasc Med. 2001; 2(Suppl 1): S19–S25.

Madyoon

Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients. Cathet Cardiovasc Intervent. 2001; 53: 341–5.

Madyoon

Clinical experience with the use of fenoldopam for prevention of radiocontrast nephropathy in high risk patients. Rev Cardiovasc Med. 2001; 2(Suppl 1): S26–S30 [duplicate publication; results not included in table].

Bakris

G.L.

Renal hemodynamics in radiocontrast medium induced renal dysfunction: A role for dopamine-1 receptors. Kidney Int. 1999; 56: 206–10.

Brady

H.R.

, Singer

G.G.

Acute renal failure. Lancet. 1995; 346: 1533–40.

Lepor

N.E.

Radiocontrast nephropathy: Managing the high risk patient. Rev Cardiovasc Med. 2001; 2(Suppl 1): S1–3.

Levy

E.M.

The effect of acute renal failure on mortality: A cohort analysis. JAMA. 1996; 275: 1489–94.

Mathur

V.S.

Pathiophysiology of radiocontrast nephropathy and use of fenoldopam for its prevention. Rev Cardiovasc Med. 2001; 2(Suppl 1): S4–8.

Parfrey

P.S.

Contrast nephrotoxicity: A randomized controlled trial of a nonionic and an ionic radiographic contrast agent. N Engl J Med. 1989; 320: 149–53.

10.

Rudnick

M.R.

Contrast media associated nephrotoxicity. Sem Nephrol. 1997; 17: 15–26.

11.

Singer

, Epstein

Potential of dopamine A-1 agonists in the management of acute renal failure. Am J Kidney Diseases. 1998; 31(5): 743–55.

12.

Solomon

Contrast medium induced acute renal failure. Kidney Int. 1998; 53: 230–42.

13.

Stevens

M.A.

A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy. J Am Coll Cardiol. 1999; 33: 403–11.

14.

Stone

G.W.

Design and rationale of CONTRAST-a prospective randomized, placebo controlled trial of fenoldopam mesylate for the prevention of radiocontrast nephropathy. Rev Cardiovasc Med. 2001; 2(Suppl 1): S31–36.